Abbott Laboratories (ABT)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$108.33-0.42%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · ABT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 4.2% |
| Our one-year growth estimate | diamond | 12.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 8.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers
ABT — litigation filed
Dated 2026-08-20
Other Events. As previously reported in Abbott’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, Abbott is a defendant in numerous lawsuits alleging that preterm infants developed necrotizing enterocolitis (“NEC”) as a result of being administered certain of Abbott’s preterm infant formula products. In a July 2024 Missouri state court trial, a jury awarded a plaintiff (“ Gill ”) $495 mil…
Why it matters: Approval would let Abbott provide more products for heart care.
Supportive ifFDA approval granted for the Amulet 360 device.
Worry ifFDA delays or denies approval for the Amulet 360 device.
Why it matters: New lawsuits might hurt Abbott's reputation and finances.
Worry ifNo new major lawsuits or settlements reported.
Less concerning ifNew lawsuits or bad rulings about preterm infant formulas.
Why it matters: The court's approval of the settlement could fix legal problems. It may also improve governance.
Supportive ifThe court approves the proposed settlement on June 4, 2026.
Worry ifThe court rejects the settlement or delays the hearing beyond June 4, 2026.
Why it matters: If this happens, it shows Abbott is integrating Exact Sciences well.
Supportive ifAbbott says the Exact Sciences deal will create over $100 million in savings.
Worry ifAbbott says the Exact Sciences deal will create less than $100 million in savings.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$103 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $223 loss on $10,000 · 2.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,861 loss on $10,000 · 38.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Changes in sales growth guidance can show how well Abbott is doing in a tough market.
Watch forAbbott raises its full-year 2026 sales growth guidance to above 7.5%.
Also watch forAbbott lowers its full-year 2026 sales growth guidance to below 6.5%.
Why it matters: Lawsuits may harm Abbott's reputation. They could also impact its finances.
Worry ifThere may be a settlement or good ruling in the NEC lawsuit.
Less concerning ifNew bad rulings or big settlements could raise financial risks.
Why it matters: This growth rate is a key target for Abbott. Falling below it could signal weakening demand.
Worry ifQ3 comparable sales growth was below 6.5%.
Less concerning ifQ3 comparable sales growth reported at or above 6.5%.
Why it matters: This EPS figure is part of Abbott's guidance. Missing it could indicate profit pressure.
Worry ifQ3 adjusted diluted EPS was below $1.25.
Less concerning ifQ3 adjusted diluted EPS reported at or above $1.25.
Why it matters: Getting benefits from this purchase is key for Abbott's growth.
Supportive ifManagement says they are making progress to reach at least $100 million in yearly pre-tax benefits.
Worry ifThere are no updates or signs of progress on synergy benefits.